9 6 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • A U G U S T 2 0 1 8
• Refractive cataract surgery. Interest in multifocal IOLs, toric
IOLs and intraoperative wavefront aberrometry remains high, but
the numbers are down slightly from last year: 80% of our respon-
dents use multifocal IOLs and 88% use toric IOLs. Meanwhile,
42% perform arcuate corneal incisions, 16% do intraoperative
wavefront aberrometry and 23% have microscopes that can digi-
tally mark the eye for toric alignment and arcuate incisions.
• Optical coherence tomography. Facilities are slowly adopting
this technology on their microscopes — 8% have it now; last year
only 4.6% did.
• FDA approval on drugs. We asked about using FDA-approved
drugs vs. compounded ones for intracameral applications. More
than half (53%) said it was "very important'" and another 22% said
it was "somewhat important." A Minnesota director of surgery
says there's "a lot of nervousness regarding compounded phar-
5 Takeaways From Our 2018 Cataract Survey
A FEW MORE FINDINGS
administered at the conclusion of surgery treats post-op inflammation
and dispenses with eye drops after cataract surgery, says Icon
Bioscience, maker of the corticosteroid. More than half of our respon-
dents like the concept, 13% finding it "very" attractive and 41% finding it
"somewhat" attractive.
"I would love to eliminate post-op drops for the patient anyway I
can," says Ms. Picano-Wilson. "Anything to reduce drops is a win-win
for all of us," adds John Kraves, BSN, ASC manager at Northwest Eye
Surgeons in Renton, Wash.
Two worries, however. First and most important, the cost. "Cost is
the biggest issue here," says a Missouri ASC administrator. What will
